August 2024
Gilead’s $4.3B Acquisition of CymaBay Yields FDA Approval for Autoimmune Liver Disease Treatment
Gilead Sciences, CymaBay, FDA Approval, Autoimmune Liver Disease, Seladelpar, Primary Biliary Cholangitis
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Evotec Announces 400 Job Cuts Amid Market Challenges
Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing
Eli Lilly Unveils State-of-the-Art Genetic Medicine Research Center in Boston
Eli Lilly, Boston, genetic medicines, research center, innovation hub, biotech
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
Rivus Advances in Obesity-Related Heart Failure with Mid-Stage Success of HU6
Rivus Pharmaceuticals, HU6, obesity-related heart failure, Phase IIa HuMAIN trial, controlled metabolic accelerator, muscle-preserving weight loss
Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection
Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval